Skip to main content

How to Leverage Pathologic Assessments to Guide Evidence-Based AML Care Planning

Authors: Courtney D. DiNardo, MD, MSCE, Joseph D. Khoury, MD, FCAP, CMQ, Jerald Radich, MD

CME / ABIM MOC Released: 07/30/2021
Valid for credit through: 07/30/2022

Target Audience and Goal Statement This educational program is directed toward pathologists and medical oncologists who treat patients with AML. Nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment and management of hematologic malignancies, specifically AML, will also be invited to participate in the activity.

This educational activity focuses on optimizing pathologic assessment and management of patients with acute myeloid leukemia (AML) and includes a discussion of the latest diagnostic guidelines in AML, current targeted treatments, and optimal application of novel diagnostic and therapeutic strategies. A multidisciplinary panel of oncology pathologists and medical oncologists consider evolving pathologic testing methodologies, including the role of measurable residual disease (MRD) in diagnosis and treatment guidance and implementation of a collaborative approach to relevant and challenging clinical cases.

Acknowledgement of Commercial Support This activity is supported by an educational grant from AbbVie, Inc.

Learning Objective
Upon completion of this activity, participants will:
  • Outline current guideline-based recommendations for pathologic testing in AML including recent updates to CAP-ASH guidelines.
  • Assess the roles for multidisciplinary team members to incorporate prognostic and predictive biomarker testing along the disease continuum in AML.
  • Evaluate recently reported safety and efficacy for evolving treatment options among patients with AML.
  • Explain AML testing methodologies and how these may be applied to facilitate diagnosis and monitoring of patients with these hematologic malignancies.

Continuing Medical Education

For Physicians
  • Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity